Clinical Trial Update: Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

This document reports a Phase 2 neoadjuvant trial evaluating the combination of tislelizumab and afatinib for resectable head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Gilotrif (Afatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED